Juniper Pharma Services Expands Laboratory Facilities

June 19, 2018
Pharmaceutical Technology Editors
Pharmaceutical Technology's In the Lab eNewsletter
Volume 13, Issue 7

The extension provides four additional process development laboratories at its Nottingham site to improve output and efficiency in drug development and clinical trial manufacturing operations.

Contract development and manufacturing organization (CDMO) Juniper Pharma Services (JPS) announced on June 19, 2018 that it is expanding its drug development and clinical trial manufacturing facilities in the United Kingdom to meet increasing demand. The extension provides four additional process development laboratories at its Nottingham site to improve operation output and efficiency.

JPS expects the new laboratory space to be fully operational by mid 2018.The expansion will ensure that processing and formulation work is scalable, enabling the efficient manufacture of stability and clinical batches.

“We are always exploring opportunities to extend our service offerings to meet the evolving requirements of our market and clients. This facility expansion, which has significantly increased Juniper Pharma Services’ capacity, is the latest effort in this endeavour,” said Nikin Patel, president at JPS, in a press statement.

Source: Juniper Pharma Services